Skip to main content
SpringerLink
Log in

Etiology of Benign Prostatic Hyperplasia: Can this Disease Be Prevented?

  • Chapter
Benign Prostatic Hyperplasia

Abstract

The term “benign prostatic hyperplasia” (BPH) is commonly used to represent either (a) a pathologic entity, or (b) a clinical diagnosis, or (c) a treatment decision based on a clinical diagnosis. In order to discuss constructively what is known about the etiology of BPH it is essential to distinguish these different meanings of the term (Isaacs and Coffey 1989). In this paper we will concentrate Ion discussing what is known of the etiology of the pathologic entity (which we will denote as pBPH) and of the clinical diagnosis of BPH (cBPH). Discussion of the issues involved in the decision as to whether and how to treat cBPH can be found in other chapters of this book.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Barry MJ (1990) Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 17:495–507

    PubMed  CAS  Google Scholar 

  • Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474–479

    PubMed  CAS  Google Scholar 

  • Brochu M, Belanger A (1987) Comparative study of plasma steriod and steriod glucuronide levels in normal men and in men with benign prostatic hyperplasia. Prostate 11:33–40

    Article  PubMed  CAS  Google Scholar 

  • Chang HL, Char GY (1936) Benign hypertrophy of prostate. Chin Med J 50:1707–1722

    Google Scholar 

  • Chopra I J, Tulchinsky D, Greenway FL (1973) Estrogen-androgen imbalance in hepatic cirrohsis, Ann Intern Med 79:198–203

    PubMed  CAS  Google Scholar 

  • Dai WS, Gutai JP, Kuller LH, Cauley JA (1988) Cigarette smoking and serum sex hormones in men. Am J Epidemiol 128:796–805

    PubMed  CAS  Google Scholar 

  • de Jong FH, Oishi K, Hayes RB, et al. (1991) Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study. Cancer Res 51:3445–3450

    PubMed  Google Scholar 

  • Ekman P (1989) BPH epidemiology and risk factors. Prostate Suppl 2:23–31

    Article  PubMed  CAS  Google Scholar 

  • Eldrup E, Lindholm J, Winkel P (1987) Plasma sex hormones and ischemic heart disease. Clin Biochem 20:105–112

    Article  PubMed  CAS  Google Scholar 

  • Evans GS, Chandler JA (1987) Cell proliferation studies in the rat prostate. II. The effects of castration and androgen-induced regeneration upon basal and secretory cell proliferation. Prostate 11:339–351

    Article  PubMed  CAS  Google Scholar 

  • Franks LM (1954) Benign nodular hyperplasia of the prostate: a review. Ann R Coll Surg Engl 14:92–106

    Google Scholar 

  • Garraway WM, Collins GN, Lee RJ (1991) High prevalence of benign prostatic hypertrophy in the community. Lancet 338:469–471

    Article  PubMed  CAS  Google Scholar 

  • Ghanadian R, Lewis JG, Chisholm GD, Donoghue EPN (1977) Serum dihydrotestosterone in patients with benign prostatic hypertrophy. Br J Urol 49:541–544

    Article  PubMed  CAS  Google Scholar 

  • Glynn RJ, Campion EW, Bouchard GR, Silbert JE (1985) The development of benign prostatic hyperplasia among volunteers in the normative aging study. Am J Epidemiol 121:78–90

    PubMed  CAS  Google Scholar 

  • Gordon GG, Altman K, Southren AL, Rubin E, Lieber CS (1976) Effect of alcohol (ethanol) administration on sex-hormone metabolism in normal men. N Engl J Med 295:793–797

    Article  PubMed  CAS  Google Scholar 

  • Guess HA (1992) Benign prostatic hyperplasia: antecedents and natural history. Epidemiol Rev 14:131–153

    PubMed  CAS  Google Scholar 

  • Guess HA, Arrighi HM, Metter EJ, Fozard JL (1990) Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate 17:241–246

    Article  PubMed  CAS  Google Scholar 

  • Hammond GL, Kontturi M, Vihko P, Vihko R (1978) Serum steroids in normal males and patients with prostatic diseases. Clin Endocrinol 9:113–121

    Article  CAS  Google Scholar 

  • Hastak SM, Gammelgaard J, Holm HH (1982) Transrectal ultrasonic volume determination of the prostate-a preoperative and postoperative study. J Urol 127:1115–1118

    PubMed  CAS  Google Scholar 

  • Ho S-M, Yu M, Leav I, Viccione T (1992) The conjoint actions of androgens and estrogens in the induction of proliferative lesions in the rat prostate. In: Li J (ed) Hormonal carcinogenesis. Springer, Berlin Heidelberg New York, pp 18–26

    Chapter  Google Scholar 

  • Hulka BS, Hammond JE, DiFerdinando G, et al. (1987) Serum hormone levels among patients with prostatic carcinoma or benign prostatic hyperplasia and clinic controls. Prostate 11:171–182

    Article  PubMed  CAS  Google Scholar 

  • Imperato-McGinley J (1984) 5α reductase deficiency in man. Prog Cancer Res Ther 31:491–495

    Google Scholar 

  • Isaacs JT, Coffey DS (1989) Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 2:33–50

    Article  PubMed  CAS  Google Scholar 

  • Jakobsen H, Torp-Pedersen S, Haid T (1988a) The long-term influence of vasectomy on prostatic volume and morphology in man. Prostate 13:57–67

    Article  PubMed  CAS  Google Scholar 

  • Jakobsen H, Torp-Pedersen S, Juul N (1988b) Ultrasonic evaluation of age-related human prostatic growth and development of benign prostatic hyperplasia. Scand J Urol Nephrol 107:26–31

    CAS  Google Scholar 

  • Karube K (1961) Study of latent carcinoma of the prostate in the Japanese based on necropsy material. Tohoku J Exp Med 74:265–285

    Article  PubMed  CAS  Google Scholar 

  • Lookingbill DP, Demers LM, Wang C, Leung A, Rittmaster RS, Santen RJ (1991) Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J Clin Endocrinol Metab 72:1242–1248

    Article  PubMed  CAS  Google Scholar 

  • McConnell JD (1990) Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. Urol Clin North Am 17:661–670

    PubMed  CAS  Google Scholar 

  • McNeal JE (1988) Normal histology of the prostate. Am J Surg Pathol 12:619–633

    Article  PubMed  CAS  Google Scholar 

  • McPherson K, Wennberg JE, Hovind OB, Clifford P (1982) Small-area variations in the use of common surgical procedures: an international comparison of New England and Norway. N Engl J Med 307:1310–1314

    Article  PubMed  CAS  Google Scholar 

  • Moore RA (1994) Benign hypertrophy and carcinoma of the prostate. Surgery 16:152–167

    Google Scholar 

  • Morrison AS (1992) Risk factors for surgery for prostatic hypertrophy. Am J Epidemiol 135:974–980

    PubMed  CAS  Google Scholar 

  • Ohnishi K, Watanabe H, Ohe H (1987) Development of benign prostatic hypertrophy estimated from ultrasonic measurement with long-term follow up. Tohoku J Exp Med 151:51–56

    Article  PubMed  CAS  Google Scholar 

  • Okafor PIS, Wild SR, Beynon LL, Chisholm GD (1983) Progress in transrectal ultrasonography for prostatic disease. Br J Urol 55:721–725

    Article  PubMed  CAS  Google Scholar 

  • Peters CA, Walsh PC (1987) The effect of nafarelin acetate, a luteinzing-hormone-releasing-hormone agonist, on benign prostatic hyperplasia. N Engl J Med 317:599–604

    Article  PubMed  CAS  Google Scholar 

  • Pollack HM (1991) Imaging of the prostate gland. Eur Urol 20 (Suppl): 50–58

    PubMed  Google Scholar 

  • Ross R, Bernstein L, Lobo R, et al. (1992) 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339:887–889

    Article  PubMed  CAS  Google Scholar 

  • Serio M, Fiorelli G (1991) Dual control by androgen and peptide growth factors of prostatic growth in human benign prostatic hyperplasia. Mol Cell Endrocrinol 78. C77-C81

    Article  CAS  Google Scholar 

  • Shapiro E (1990) Embryologie development of the prostate. Urol Clin North Am 17:487–493

    PubMed  CAS  Google Scholar 

  • Sidney S (1987) Vasectomy and the risk of prostatic cancer and benign prostatic hypertrophy. J Urol 138:795–797

    PubMed  CAS  Google Scholar 

  • Sidney S, Quesenberry C Jr, Sadler MC, Lydick EG, Guess HA, Cattolica EV (1991) Risk factors for surgically treated benign prostatic hyperplasia in a prepaid health care plan. Urology 38:13–19

    Article  PubMed  CAS  Google Scholar 

  • Skoldefors H, Blomstedt B, Carlstrom K (1978) Serum hormone levels in benign prostatic hyperplasia. Scand J Urol Nephrol 12:111–114

    Article  PubMed  CAS  Google Scholar 

  • Steiner JF (1993) Finasteride: a 5α-reductase inhibitor. Clin Pharm 12:15–23

    PubMed  CAS  Google Scholar 

  • Stoner E, Group TFS (1992) The clinical effects of a 5α-reductase inhibitor, finasteride, on benign prostatic hyperplasia. J Urol 147:1298–1302

    PubMed  CAS  Google Scholar 

  • Stumpf HH, Wilens SL (1953) Inhibitory effects of portal cirrhosis of liver on prostatic enlargement. Arch Intern Med 91:304–309

    CAS  Google Scholar 

  • Swyer GIM (1944) Post-natal growth changes in the human prostate. J Anat 78:130–145

    PubMed  CAS  Google Scholar 

  • Torp-Pedersen S, Juul N, Jakobsen H (1988) Transrectal prostatic ultrasonography: equipment, normal findings, benign hyperplasia and cancer. Scand J Urol Nephrol 107:19–25

    CAS  Google Scholar 

  • Vermeulen A, de Sy W (1976) Androgens in patients with benign prostatic hyperplasia before and after prostatectomy. J Clin Endocrinol Metab 43:1250–1254

    Article  PubMed  CAS  Google Scholar 

  • Walsh PC, Wilson JD (1976) The induction of prostatic hypertrophy in the dog with androstanediol. J Clin Invest 57:1093–1097

    Article  PubMed  CAS  Google Scholar 

  • Walsh PC, Hutchins GM, Ewing LL (1983) Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supranormal. J. Clin Invest 72:1772–1777

    Article  PubMed  CAS  Google Scholar 

  • Wilson J (1980) The pathogenesis of benign prostatic hyperplasia. Am J Med 68:745–756

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Preventive Medicine, University of Southern California School of Medicine, 1420 San Pablo Street, 90033-9987, Los Angeles, CA, USA

    Malcolm C. Pike PhD (Professor and Chairman) & Giske Ursin MD, PhD (Post-doctoral Fellow)

Authors
  1. Malcolm C. Pike PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giske Ursin MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Kenneth Norris Jr. Cancer Center, University of Southern California, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA

    Zbigniew Petrovich MD (Professor and Chairman) (Professor and Chairman)

  2. Department of Urology, St. Pieter’s Hospital, Catholic University of Leuven, Brusselsestraat 69, 3000, Leuven, Belgium

    Luc Baert MD, PhD (Professor and Chairman, Clinical Professor of Urology and Radiation Oncology) (Professor and Chairman, Clinical Professor of Urology and Radiation Oncology)

  3. School of Medicine, University of Southern California, 90033, Los Angeles, CA, USA

    Luc Baert MD, PhD (Professor and Chairman, Clinical Professor of Urology and Radiation Oncology) (Professor and Chairman, Clinical Professor of Urology and Radiation Oncology)

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Pike, M.C., Ursin, G. (1994). Etiology of Benign Prostatic Hyperplasia: Can this Disease Be Prevented?. In: Petrovich, Z., Baert, L. (eds) Benign Prostatic Hyperplasia. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78185-8_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-78185-8_1

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-78187-2

  • Online ISBN: 978-3-642-78185-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation